A double-blind, randomized, placebo/active controlled crossover evaluation of the efficacy and safety of Ritalin® la in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting

Journal of Child and Adolescent Psychopharmacology

Volumn 20, Issue 5, 2010, Pages 377-385

  Schulz, Eberhard ^a   Fleischhaker, Christian ^a   Hennighausen, Klaus ^a   Heiser, Philip ^a   Oehler, Klaus Uwe ^b   Linder, Martin ^c   Haessler, Frank ^d   Huss, Michael ^e   Warnke, Andreas ^f   Schmidt, Martin ^g   Schulte Markworth, Michael ^h   Sieder, Christian ⁱ   Klatt, Jan ⁱ   Tracik, Ferenc ⁱ  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Office for Child and Adolescent Psychiatry   (Germany)

^c Hochschule Regensburg   (Germany)

^d ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^f UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^g CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^h UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

ⁱ NOVARTIS PHARMA GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; PLACEBO;

ABDOMINAL PAIN; ACUTE APPENDICITIS; ADOLESCENT; AGGRESSION; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHOOL CHILD; SIDE EFFECT;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 77958562405     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2009.0106     Document Type: Article

References (34)

1. Aman MG: The Nisonger Child Behavior Rating Form-TIQ Version. Parent behavior ratings for children of average IQ. Unpublished manuscript. Columbus (Ohio): The Ohio State University, 2002.
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4 edition (DSM-IV). Washington (DC): American Psychiatric Association, 1994.
3. Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Döpfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJ, Taylor E: Long acting medications for the hyperkinetic disorders-A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 15:476-495, 2006.
4. Biederman J, Faraone SV: Attention-deficit hyperactive disorder. Lancet 366:237-248, 2005.
5. Biederman J, Quinn D, Weiss M, Markabi S, Weidenman M, Edson K, Karlsson G, Pohlmann H, Wigal S: Efficacy and safety of Ritalin® LA, a new once daily extended-release dosage form of methylphenidate in children with attention deficit hyperactivity disorder. Pediatr Drugs 5:833-841, 2003
6. Delmo C, Weiffenbach O, Gabriel M, Stadler C, Poustka F: Kiddie-Sads-Present and Lifetime Version (K-SADS-PL): Auflage der Deutsche Forschungsversion [German Version]. 3rd ed. Frankfurt, Germany: Klinik für Psychiatrie und Psychotherapie des Kindes und Jugendalters der Universität Frankfurt, 2000.
7. Doepfner M, Banaschewski T, Schmidt J, Uebel H, Schmeck K, Gerber WD, Guenter M, Knoelker U, Gehrke M, Haessler F, Moehler E, Bruenger M, Ose C, Fischer R, Poustka F, Lehmkuhl G, Rothenberger A: Long-acting methylphenidate preparation in children with ADHD-a multicenter study. Nervenheilkunde 22:85-92, 2003.
8. Doepfner M, Gerber WD, Banaschewski T, Breuer D, Freisleder FJ, Gerber-von Mueller G, Guenter M, Haessler F, Ose C, Rothenberger A, Schmeck K, Sinzig J, Stadler C, Uebel H, Lehmkuhl G: Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur Child Adolsc Psychiatry 13(Suppl 1):I93-I101, 2004.
9. Findling RL, Quinn D, Hatch SJ, Cameron SJ, DeCory HH, McDowell M: Comparison of the clinical efficacy of twice-daily Ritalin and once daily Equasym XL with placebo in children with attention deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry 15:450-459, 2006.
10. Greenhill LL, Findling RL, Swanson JM; ADHD Study Group: A double-blind, placebo-controlled study of modified-release meth-ylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 109:e39, 2002.
11. Haessler F, Tracik F, Dietrich H, Stammer H, Klatt J: A pharmacokinetic study of two modified-release methylphenidate formulations under different food conditions in healthy volunteers. Int J Clin Pharmacol Ther 46:466-476, 2008.
12. Huss M, Hölling H, Kurth BM, Schlack R: How often are German children and adolescents diagnosed with ADHD? Prevalence based on the judgment of health care professionals: Results of the German health and examination survey (KiGGS). Eur Child Adolesc Psychiatry 17(Suppl 1):52-58, 2008.
13. Lee L, Kepple J, Wang Y, Freestone S, Bakhtiar R, Wang Y, Hossain M: Bioavailability of modified-release Methylphenidate: Influence of high-fat breakfast when administered intact and when capsule content sprinkled on applesauce. Biopharm Drug Dispos 24:233-243, 2003.
14. Lopez F, Silva R, Pestreich L, Muniz R: Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta®) and placebo in children with attention deficit hyperactivity disorder across the school day. Pediatr Drugs 5:545-555, 2003.
15. Lyseng-Williamson KA, Keating GM: Extended-release methylphenidate (Ritalin LA). Drugs 65:2251-2259, 2002.
16. Marcus SC, Wan GJ, Kemner JE, Olfson M: Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 159:572-578, 2005.
17. Modi NB, Lindemulder B, Gupta SK: Dose-proportional and stereo-specific pharmacokinetics of methylphenidate delivered using an osmotic controlled-release oral delivery system. J Clin Pharmacol 20:1141-1149, 2000.
18. Oehler KU: Frühstücksverhalten bei Kindern mit ADHS: häufig unregelmäßig und nicht ausreichend. [Breakfast in children with ADHD: Often unregularly and unsufficient] Poster presented at the BKJPP Congress, Bremen, Germany, 15-17. September 2007.
19. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD: Once-a-Day Concerta Methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107:E105, 2001.
20. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA: The worldwide prevalence of ADHD: A systematic review and meta-regression analysis. Am J Psychiatry 164:856-858, 2007.
21. Silva R, Muniz R, Pestreich LK, Brams M, Childress A, Lopez FA: Efficacy of two long-acting methylphenidate formulations in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting. J Child Adolesc Psychopharmacol 15: 637-654, 2005.
22. Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S: Pharmacotherapy of attention-deficit hyperactivity disorder across the life-cycle. J Am Acad Child Adolesc Psychiatry 35:409-432, 1996. (Pubitemid 126418605)
23. Swanson JM, Wigal SB, Udrea D, Lerner M, Agler D, Flynn D, Fineberg E, Davies M, Kardatzke D, Ram A, Gupta S: Objective and subjective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting. Psychopharmacol Bull 34:55-61, 1998.
24. Swanson JM, Volkow ND: Pharmacokinetic and pharmacodynamic properties of stimulants: Implications for the design of new treatments for ADHD. Behav Brain Res 130:73-78, 2002.
25. Swanson JM, Lerner M, Wigal T, Steinhoff K, Greenhill L, Posner K, Freid J, Wigal S: The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications. J Atten Disord 6(Suppl 1):S73-S88, 2002.
26. Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, Lindemulder E, Wigal S: Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperac-tivity disorder: Proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 60:204-211, 2003.
27. Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ; COMACS Study Group: A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the COMACS Study). Pediatrics 113(3 Pt 1):e206-e216, 2004.
28. Tuerck D, Appel-Dingemanse S, Maboudian M, Pommier F, Wang Y, Sedek G: Dose-proportional pharmacokinetics of d-threo-methyl-phenidate after a repeated-action release dosage form. J Clin Pharmacol 47: 64-69, 2007.
29. Volkow ND, Wang GJ, Fowler JS, Ding YS: Imaging the effects of methylphenidate on brain dopamine: New model on its therapeutic actions for attention deficit/hyperactivity disorder. Biol Psychiatry 57:1410-1415, 2005.
30. Wigal SB, Gupta S, Guinta D, Swanson JM: Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psycho-pharmacol Bull 34:47-53, 1998.
31. Wilens T, McBurnett K, Stein M, Lerner M, Spencer T, Wolraich M: ADHD treatment with once-daily OROS methylphenidate: Final results from a long-term open study. J Am Acad Child Adolesc Psychiatry 44:1015-1023, 2005.
32. Wolraich ML, Doffing MA: Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methyl-phenidate. CNS Drugs 18:243-250, 2004.
33. Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, McBurnett K, Bukstein O, August G: Randomized controlled trial of OROS methylphenidate once a day in children with attention deficit/hyperactivity disorder. Pediatrics 108:883-892, 2001.
34. Wolraich ML, McGuinn L, Doffing M: Treatment of attention deficit hyperactivity disorder in children and adolescents-safety considerations. Drug Safety 30:17-26, 2007.